A Syndromic Approach to COVID-19 Diagnostics

Supported by BioFire Diagnostics, LLC


The global COVID-19 pandemic has forever changed diagnostics for acute respiratory infections. Now, more than ever, it is important to quickly and accurately identify the source of respiratory illness, particularly as we enter an unprecedented respiratory season. BioFire’s syndromic respiratory solution, authorized by the FDA through an Emergency Use Authorization, includes the ability to identify SARS-CoV-2, along with 21 additional common respiratory pathogens, in about 45 minutes. Dr. Ginocchio will present on the evolution of the COVID-19 pandemic, the rapidly evolving SARS-CoV-2 testing landscape, and clinical and analytical performance data of BioFire’s respiratory solution.


Christine C. Ginocchio, PhD, MT (ASCP)
VP, Global Medical Affairs
bioMérieux/BioFire Diagnostics